

Stanley Cohan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6973682/publications.pdf>

Version: 2024-02-01

13
papers

341
citations

1307594

7
h-index

1125743

13
g-index

14
all docs

14
docs citations

14
times ranked

560
citing authors

#	ARTICLE	IF	CITATIONS
1	Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: An observational study using the US Department of Defense administrative claims database. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 546-554.	2.0	87
2	Evaluating the Utility of Smartphone-Based Sensor Assessments in Persons With Multiple Sclerosis in the Real-World Using an App (elevateMS): Observational, Prospective Pilot Digital Health Study. <i>JMIR MHealth and UHealth</i> , 2020, 8, e22108.	3.7	55
3	Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY). <i>Multiple Sclerosis and Related Disorders</i> , 2018, 22, 27-34.	2.0	41
4	Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. <i>BMC Neurology</i> , 2016, 16, 117.	1.8	40
5	Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis. <i>Biomedicines</i> , 2019, 7, 18.	3.2	38
6	Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study. <i>Multiple Sclerosis Journal</i> , 2018, 24, 795-804.	3.0	37
7	The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis. <i>CNS Drugs</i> , 2022, 36, 703-719.	5.9	18
8	Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis. <i>Biologics: Targets and Therapy</i> , 2016, Volume 10, 119-138.	3.2	7
9	Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison. <i>CNS Drugs</i> , 2021, 35, 795-804.	5.9	5
10	Outcomes of Stable Multiple Sclerosis Patients Staying on Initial Interferon Beta Therapy Versus Switching to Another Interferon Beta Therapy: A US Claims Database Study. <i>Advances in Therapy</i> , 2018, 35, 1894-1904.	2.9	4
11	Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642098794.	3.5	4
12	Results of sustained long-term use of interferon beta-1a in a community-based cohort of patients with relapsing multiple sclerosis. <i>Journal of Drug Assessment</i> , 2015, 4, 1-6.	2.2	3
13	Matching-adjusted indirect treatment comparison of ozanimod versus teriflunomide for relapsing multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 52, 102972.	2.0	2